Pasi Score Calculator
Calculate Psoriasis Area and Severity Index from body region involvement and lesion severity. Enter values for instant results with step-by-step formulas.
Formula
PASI = 0.1(Ah)(Eh+Ih+Dh) + 0.3(At)(Et+It+Dt) + 0.2(Au)(Eu+Iu+Du) + 0.4(Al)(El+Il+Dl)
Where A = area score (0-6), E = erythema (0-4), I = induration (0-4), D = desquamation (0-4) for each region. Weighting: head (h) = 0.1, trunk (t) = 0.3, upper extremities (u) = 0.2, lower extremities (l) = 0.4. Total PASI ranges from 0 (clear) to 72 (maximum severity).
Worked Examples
Example 1: Moderate Plaque Psoriasis Assessment
Problem: A patient has: Head - area 2, erythema 2, induration 2, scaling 1. Trunk - area 3, erythema 2, induration 2, scaling 2. Upper limbs - area 2, erythema 2, induration 1, scaling 1. Lower limbs - area 3, erythema 2, induration 2, scaling 2. Calculate PASI.
Solution: Head: 0.1 x 2 x (2+2+1) = 0.1 x 2 x 5 = 1.0\nTrunk: 0.3 x 3 x (2+2+2) = 0.3 x 3 x 6 = 5.4\nUpper: 0.2 x 2 x (2+1+1) = 0.2 x 2 x 4 = 1.6\nLower: 0.4 x 3 x (2+2+2) = 0.4 x 3 x 6 = 7.2\nTotal PASI = 1.0 + 5.4 + 1.6 + 7.2 = 15.2
Result: PASI: 15.2 | Moderate Psoriasis | PASI 75 target: 3.8
Example 2: Treatment Response at 12 Weeks
Problem: Baseline PASI was 22.0. At 12 weeks on biologic therapy, PASI is 4.4. Calculate response level.
Solution: Baseline PASI: 22.0\nCurrent PASI: 4.4\nAbsolute reduction: 22.0 - 4.4 = 17.6\nPercent reduction: (17.6/22.0) x 100 = 80%\nPASI 75 threshold: 22.0 x 0.25 = 5.5 (achieved, current 4.4 < 5.5)\nPASI 90 threshold: 22.0 x 0.10 = 2.2 (not yet achieved)\nResponse: PASI 75 achieved, approaching PASI 90
Result: 80% improvement | PASI 75 achieved | Continue current therapy
Frequently Asked Questions
What is the PASI score and why is it important in dermatology?
The Psoriasis Area and Severity Index (PASI) is the gold standard clinical tool for measuring psoriasis severity, combining assessment of body surface area involvement with lesion characteristics. Developed by Fredriksson and Pettersson in 1978, it evaluates four body regions (head, trunk, upper extremities, and lower extremities) across three lesion parameters: erythema (redness), induration (thickness), and desquamation (scaling). PASI scores range from 0 to 72, with higher scores indicating more severe disease. The PASI is the primary endpoint in virtually all clinical trials of psoriasis treatments and is required by regulatory agencies including the FDA and EMA for drug approval in psoriasis. It provides a standardized, reproducible measure for tracking disease progression and treatment response.
How is the PASI score calculated step by step?
The PASI score is calculated by evaluating four body regions separately and then combining their weighted contributions. For each region (head, trunk, upper extremities, lower extremities), the clinician rates three lesion characteristics on a 0-4 scale: erythema, induration, and desquamation. These three severity scores are summed for each region. The area of involvement for each region is graded on a 0-6 scale (0 = none, 1 = less than 10%, up to 6 = 90-100%). Each region score equals the area grade multiplied by the severity sum. Regional scores are then multiplied by body surface area weighting factors: head = 0.1, trunk = 0.3, upper extremities = 0.2, and lower extremities = 0.4. The final PASI is the sum of all four weighted regional scores.
What do different PASI score ranges indicate about disease severity?
PASI scores are categorized into severity bands that guide clinical management decisions. A PASI of 0 indicates clear or completely resolved psoriasis. Scores from 0.1 to 5 represent mild psoriasis, typically manageable with topical treatments alone. Scores between 5 and 10 indicate mild-to-moderate disease that may require phototherapy or systemic therapy. Scores above 10 are generally classified as moderate-to-severe psoriasis warranting systemic or biologic therapy. Scores above 20 indicate severe psoriasis requiring aggressive intervention. In clinical trials, PASI thresholds of 10 or 12 are commonly used as inclusion criteria for moderate-to-severe disease. Most dermatology guidelines now use PASI alongside body surface area and quality-of-life measures for comprehensive severity classification.
What are PASI 75, PASI 90, and PASI 100 response criteria?
PASI response criteria express the percentage improvement from baseline PASI score and are the standard endpoints in psoriasis clinical trials. PASI 75 means a 75% or greater reduction from baseline PASI and has traditionally been the primary efficacy endpoint in most clinical trials. PASI 90 represents a 90% or greater reduction and is increasingly used as the primary endpoint for newer biologic therapies that achieve higher clearance rates. PASI 100 indicates complete clearance of all psoriasis lesions. For example, a patient with baseline PASI of 20 would need to achieve PASI 5 or lower for PASI 75, PASI 2 or lower for PASI 90, and PASI 0 for PASI 100. Modern biologic therapies like IL-17 and IL-23 inhibitors commonly achieve PASI 90 rates of 60-80%.
How reliable is the PASI score between different clinicians?
Inter-rater reliability of PASI scoring has been a persistent concern in dermatology research. Studies show moderate to good inter-rater agreement with intraclass correlation coefficients ranging from 0.60 to 0.85 depending on training and experience. The area component tends to have lower reliability than the severity components because estimating percentage body surface area involvement is inherently subjective. Training programs and photographic reference atlases can improve consistency. Erythema assessment can be challenging in patients with darker skin types due to reduced contrast between inflamed and uninflamed skin. Despite these limitations, PASI remains the most widely used psoriasis severity measure because alternatives have not demonstrated clearly superior reliability while maintaining the same breadth of clinical validation and regulatory acceptance.
What are the limitations of using PASI as the primary severity measure?
PASI has several well-recognized limitations despite its widespread use. It does not capture important aspects of psoriasis burden such as symptoms (itch, pain, burning), quality of life impact, joint involvement, or nail and scalp disease severity. The scoring system has limited sensitivity at lower disease severity levels, making it less useful for differentiating between mild and very mild psoriasis. PASI cannot distinguish between different clinical subtypes of psoriasis (plaque, guttate, pustular, erythrodermic). The mathematical weighting system may undervalue highly visible areas like the face and hands. Additionally, patients with identical PASI scores may have vastly different disease patterns and functional impact. For these reasons, modern guidelines recommend using PASI alongside patient-reported outcomes like DLQI and body surface area assessment.